Evidence map›Paper›PMID 26081808›Full record

ArticleCancer research2015

Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer.

Juan Du, John A Cieslak, Jessemae L Welsh, Zita A Sibenaller, Bryan G Allen, Brett A Wagner, Amanda L Kalen, Claire M Doskey, Robert K Strother, Anna M Button and 8 more

Abstract read
In one paragraph

Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 111 citations in OpenAlex.

  1. OCancer cell · 2017
    Trial
  2. Article
  3. Iranian journal of basic medical sciences · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Balanced Duality: HInternational journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
  14. Differential HInternational journal of molecular sciences · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Metabolic targeting of malignant tumors: a need for systemic approach.Journal of cancer research and clinical oncology · 2023
    Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Juan DuDepartment of Surgery, University of Iowa College of Medicine, Iowa City, Iowa.
John A CieslakDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa.
Jessemae L WelshDepartment of Surgery, University of Iowa College of Medicine, Iowa City, Iowa.
Zita A SibenallerDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa.
Bryan G AllenDepartment of Surgery, University of Iowa College of Medicine, Iowa City, Iowa. Holden Comprehensive Cancer Center, Iowa City, Iowa.
Brett A WagnerDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa.
Amanda L KalenDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa.
Claire M DoskeyDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa.
Robert K StrotherDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa.
Anna M ButtonHolden Comprehensive Cancer Center, Iowa City, Iowa.
Sarah L MottHolden Comprehensive Cancer Center, Iowa City, Iowa.
Brian SmithHolden Comprehensive Cancer Center, Iowa City, Iowa.
Susan TsaiMedical College of Wisconsin, Milwaukee, Wisconsin.
James MezhirDepartment of Surgery, University of Iowa College of Medicine, Iowa City, Iowa. Holden Comprehensive Cancer Center, Iowa City, Iowa.
Prabhat C GoswamiDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa. Holden Comprehensive Cancer Center, Iowa City, Iowa.
Douglas R SpitzDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa. Holden Comprehensive Cancer Center, Iowa City, Iowa.
Garry R BuettnerDepartment of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa. Holden Comprehensive Cancer Center, Iowa City, Iowa.
Joseph J CullenDepartment of Surgery, University of Iowa College of Medicine, Iowa City, Iowa. Department of Radiation Oncology, University of Iowa College of Medicine, Iowa City, Iowa. Holden Comprehensive Cancer Center, Iowa City, Iowa. Veterans Affairs Medical Center, Iowa City, Iowa. joseph-cullen@uiowa.edu.
Iowa City VA Medical Center · USMedical College of Wisconsin · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
Training CoreP42ES013661 · NIEHS · UNIVERSITY OF IOWA · PI HANS-JOACHIM LEHMLER · 2006 to 2026
$60.3M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
TRAINING PROGRAM IN FREE RADICAL AND RADIATION BIOLOGYT32CA078586 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 1999 to 2024
$5.7M
SHORT-TERM TRAINING: STUDENTS IN HEALTH PROF. SCHOOLST35HL007485 · NHLBI · UNIVERSITY OF IOWA · PI ROGHAIR, ROBERT D · 1985 to 2019
$4.3M
University of Iowa Surgical Oncology Training GrantT32CA148062 · NCI · UNIVERSITY OF IOWA · PI WEIGEL, RONALD J · 2010 to 2020
$3.8M
Redox Biology of Quiescent Normal Fibroblasts and Epithelial Cancer ProgressionR01CA111365 · NCI · UNIVERSITY OF IOWA · PI GOSWAMI, PRABHAT C · 2006 to 2016
$2.1M
Enhancing Metabolic Oxidative Stress and Therapy Responses in Cancer Stem CellsR01CA182804 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 2014 to 2018
$1.7M
The chemical biology of pharmacological ascorbate in cancer treatmentR01CA169046 · NCI · UNIVERSITY OF IOWA · PI BUETTNER, GARRY R · 2013 to 2017
$1.6M
Pharmacological Ascorbate as a Radiosensitizer in Pancreatic CancerR01CA184051 · NCI · UNIVERSITY OF IOWA · PI CULLEN, JOSEPH J · 2015 to 2018
$1.4M
Role of HIF-1 alpha in EcSOD-Induced Growth Inhibition of Pancreatic CancerI01BX001318 · VA · IOWA CITY VA MEDICAL CENTER · PI CULLEN, JOSEPH J · 2013 to 2018
–
BLRD VA I01 BX001318NCI NIH HHS P30 CA086862NCI NIH HHS R01 CA111365NCI NIH HHS R01 CA169046NCI NIH HHS R01 CA182804NCI NIH HHS R01 CA184051NCI NIH HHS T32 CA078586NCI NIH HHS T32 CA148062NHLBI NIH HHS T35 HL007485NIEHS NIH HHS P30 ES005605NIEHS NIH HHS P42 ES013661
6 · The paper itself

Abstract

The toxicity of pharmacologic ascorbate is mediated by the generation of H2O2 via the oxidation of ascorbate. Because pancreatic cancer cells are sensitive to H2O2 generated by ascorbate, they would also be expected to become sensitized to agents that increase oxidative damage such as ionizing radiation. The current study demonstrates that pharmacologic ascorbate enhances the cytotoxic effects of ionizing radiation as seen by decreased cell viability and clonogenic survival in all pancreatic cancer cell lines examined, but not in nontumorigenic pancreatic ductal epithelial cells. Ascorbate radiosensitization was associated with an increase in oxidative stress-induced DNA damage, which was reversed by catalase. In mice with established heterotopic and orthotopic pancreatic tumor xenografts, pharmacologic ascorbate combined with ionizing radiation decreased tumor growth and increased survival, without damaging the gastrointestinal tract or increasing systemic changes in parameters indicative of oxidative stress. Our results demonstrate the potential clinical utility of pharmacologic ascorbate as a radiosensitizer in the treatment of pancreatic cancer.

Indexed as

Xenograft Model Antitumor AssaysAnimalsAntioxidantsAscorbic AcidCell LineCell Line, TumorCell SurvivalChemoradiotherapyDNA DamageDose-Response Relationship, RadiationGlutathioneGlutathione DisulfideHumansHydrogen PeroxideKaplan-Meier EstimateLinear ModelsAntioxidantsAscorbic AcidGlutathioneGlutathione DisulfideHydrogen PeroxideRadiation-Sensitizing Agents

Identifiers

PMID26081808
PMCPMC4537815
OpenAlexW2106438648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.